echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Allogeneic cell therapy for the treatment of solid tumors received fast track designation

    Allogeneic cell therapy for the treatment of solid tumors received fast track designation

    • Last Update: 2022-04-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A few days ago, Allogene Therapeutics, which focuses on the development of allogeneic CAR-T therapy, announced that the US FDA has granted its innovative therapy ALLO-316 Fast Track designation


    Clear cell renal cell carcinoma is a disease with a significant unmet medical need.


    The CAR-T therapy targets CD70, which is highly expressed in renal cell carcinoma and limited in other healthy tissues


    ▲Allogene's R&D pipeline (Image source: Allogene's official website)

    Given that ALLO-316 may address an unmet need in this group of patients, the FDA granted Fast Track designation to the therapy


    References:

    [1] Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma, Retrieved March 11, 2022, from https:// /03/10/2400941/0/en/Allogene-Therapeutics-Receives-FDA-Fast-Track-Designation-for-its-First-Solid-Tumor-Candidate-ALLO-316-in-the-Treatment-of-Renal -Cell-Carcinoma.


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.